Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Takei

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 13, 2006
[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]Muneaki Sano, Toshio Tabei, Kimito Suemasu, et al.
ESMO Open|April 10, 2019
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implicationTakayuki Ueno, Shigehira Saji, Norikazu Masuda, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|January 17, 2024
Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive AnalysisYoshinobu Saito, Yasuhiro Terasaki, Takeru Kashiwada, et al.
Breast Cancer (Tokyo, Japan)|August 25, 2009
Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsiesHiroyuki Takei, Masafumi Kurosumi, Takashi Yoshida, et al.
Oncology Letters|December 21, 2012
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancerYuji Hayashi, Hiroyuki Takei, Satoshi Nozu, et al.
Breast (Edinburgh, Scotland)|August 23, 2011
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancerMasahiro Takada, Shigehira Saji, Norikazu Masuda, et al.
Genes, Chromosomes & Cancer|January 27, 2017
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapyMamoru Takada, Shigenori Nagai, Masayuki Haruta, et al.
International Journal of Clinical Oncology|October 9, 2013
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancerTakayuki Ueno, Norikazu Masuda, Takeharu Yamanaka, et al.
ESMO Open|March 14, 2018
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trialTakayuki Ueno, Shigehira Saji, Norikazu Masuda, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2019
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancerTomohiro Ochi, Giampaolo Bianchini, Michiko Ando, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 13, 2006
[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]Muneaki Sano, Toshio Tabei, Kimito Suemasu, et al.
ESMO Open|April 10, 2019
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implicationTakayuki Ueno, Shigehira Saji, Norikazu Masuda, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|January 17, 2024
Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive AnalysisYoshinobu Saito, Yasuhiro Terasaki, Takeru Kashiwada, et al.
Breast Cancer (Tokyo, Japan)|August 25, 2009
Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsiesHiroyuki Takei, Masafumi Kurosumi, Takashi Yoshida, et al.
Oncology Letters|December 21, 2012
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancerYuji Hayashi, Hiroyuki Takei, Satoshi Nozu, et al.
Breast (Edinburgh, Scotland)|August 23, 2011
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancerMasahiro Takada, Shigehira Saji, Norikazu Masuda, et al.
Genes, Chromosomes & Cancer|January 27, 2017
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapyMamoru Takada, Shigenori Nagai, Masayuki Haruta, et al.
International Journal of Clinical Oncology|October 9, 2013
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancerTakayuki Ueno, Norikazu Masuda, Takeharu Yamanaka, et al.
ESMO Open|March 14, 2018
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trialTakayuki Ueno, Shigehira Saji, Norikazu Masuda, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2019
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancerTomohiro Ochi, Giampaolo Bianchini, Michiko Ando, et al.
Pageof 18